Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock. A number of other research firms have also commented on CRNX. Morgan Stanley increased […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month […]
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Stephanie Okey sold 17,500 shares of Crinetics Pharmaceuticals stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $46.38, for a total value of $811,650.00. Following the completion of the sale, the director now owns 6,000 shares of the […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Stephanie Okey sold 17,500 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $46.38, for a total transaction of $811,650.00. Following the completion of the sale, the director now owns 6,000 shares in the […]